Our view
Some of the most important options are made for one person, or for very few: custom nucleic-acid medicines, personalised cancer vaccines, and other n-of-1 or n-of-few approaches. Getting a therapy into the right cell, and manufacturing it to a clinical standard, remain first-class problems.
We are also interested in the biology of ageing, in measuring health over time, and in the difference between adding years and adding healthy years.
01
Made for one
Custom nucleic-acid medicines and other n-of-1 or n-of-few approaches.
02
Delivery
Getting a therapy into the right cell, and making it to a clinical standard.
03
Healthy years
The biology of ageing, and adding healthy years rather than just years.
The limits we keep in view
- Many of these options are investigational, and eligibility is limited.
- Outcomes are uncertain. No pathway of this kind should be described as a cure.
- Longevity work is not a promise of extended life.